Elevation Oncology Inc (ELEV) Actualités

Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors

Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of...

Elevation Oncology Presents Preclinical Proof-of-Concept Data Supporting Combination Potential of EO-3021 with VEGFR2 or PD-1 Inhibitors at ESMO Immuno-Oncology Annual Congress 2024

Elevation Oncology Presents Preclinical Proof-of-Concept Data Supporting Combination Potential of EO-3021 with...

Elevation Oncology to Present at the Piper Sandler 36th Annual Healthcare Conference

Elevation Oncology to Present at the Piper Sandler 36th Annual Healthcare Conference PR Newswire BOSTON, Nov...

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 8-K - Current report

Elevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Achievements

Elevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Achievements PR...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2

Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult...

Form 8-K - Current report

Elevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Elevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference PR...

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Elevation Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Achievements

Elevation Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business...